Regeneron Pharmaceuticals (REGN) EBT Margin (2009 - 2026)

Regeneron Pharmaceuticals' EBT Margin history runs 18 years deep, the most recent figure standing at 23.05% for Q1 2026.

• On a quarterly basis, EBT Margin fell 683.0% year-over-year to 23.05% in Q1 2026; TTM through Mar 2026 was 34.56%, a 82.0% decrease from a year earlier, with the FY2025 full-year figure at 36.47%, up 281.0% from the prior year.
• EBT Margin fell to 23.05% in Q1 2026 per REGN's latest filing, from 26.87% in the prior quarter.
• Across five years, EBT Margin topped out at 2122.2% in Q1 2022 and bottomed at 22.28% in Q1 2024.
• The 5-year median for EBT Margin is 33.71% (2022), against an average of 233.03%.
• Across the five-year window, EBT Margin surged 207265 bps in 2022 and slumped 209507 bps in 2023, its largest moves.
• Year by year, EBT Margin stood at 1324.7% in 2022, then plunged by 97 bps to 33.42% in 2023, then dropped by 24 bps to 25.29% in 2024, then rose by 6 bps to 26.87% in 2025, then dropped by 14 bps to 23.05% in 2026.
• Per Business Quant, the three latest REGN EBT Margin figures stand at 23.05% (Q1 2026), 26.87% (Q4 2025), and 46.97% (Q3 2025).